3 research outputs found
Hemostatic System in Malignancy: Providing the βSoilβ in Metastatic Niche Formation
Malignancy arises and progresses in tight association with changes in the tumor microenvironment and deregulation of hemostatic system. Cancer induces hemostatic imbalance through production and secretion of procoagulant substances, suppression of anticoagulant mechanisms, endothelial activation, and angiogenic switch. Cancer cells are equipped with certain coagulation signaling receptors such as tissue factor (TF) and urokinase plasminogen activator receptor (uPAR). Tissue factor: as major initiator of coagulation, TF is considered the main cause for hypercoagulability in cancer. Constitutive TF expression by cancer cells is a hallmark of malignancy rendering tumors proangiogenic and prometastatic. TF fosters metastasis through coagulation-dependent pathways leading to fibrin deposition in the evolving premetastatic niche. TF has been identified as an independent predictor for metastatic development and adverse prognosis. uPAR: Tissue overexpression of uPAR is demonstrated in almost all human cancers and is associated with advanced disease. Increased uPAR expression is driven by molecular events involving K-ras and SRC oncogenes. Transactivation of these receptors, mediated by binding to hemostatic proteins, activates intracellular signaling pathways, modulates gene expression and facilitates processes of tumor initiation, epithelial-to-mesenchymal transition, anoikis, and metastasis. By manipulating hemostatic processes, tumor induces tolerant host environment necessary for evasion of defense attacks, survival, and progression
Acute Poisoning with Dapsone and Olanzapine: Severe Methemoglobinemia and Coma with a Favourable Outcome / ΠΡΡΡΠΎΠ΅ ΠΡΡΠ°Π²Π»Π΅Π½ΠΈΠ΅ ΠΠ΅Π΄ΠΈΠΊΠ°ΠΌΠ΅Π½ΡΠ°ΠΌΠΈ Dapsone Π Olanzapine: Π’ΡΠΆΡΠ»Π°Ρ ΠΠ΅ΡΠ³Π΅ΠΌΠΎΠ³Π»ΠΎΠ±ΠΈΠ½Π΅ΠΌΠΈΡ Π ΠΠΎΠΌΠ° Π‘ ΠΠ»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΌ ΠΡΡ ΠΎΠ΄ΠΎΠΌ
ΠΠ°ΠΏΡΠΎΠ½ ΡΠ²Π»ΡΠ΅ΡΡΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²ΠΎΠΌ, ΠΊΠΎΡΠΎΡΠΎΠ΅ ΠΎΠ±ΡΡΠ½ΠΎ ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΡΡΡ Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΡΠΎΠΊΠ°Π·Ρ (Π»Π΅ΠΏΡΡ). Π ΠΠ²ΡΠΎΠΏΠ΅ Π΅Π³ΠΎ ΠΏΡΠ΅Π΄ΠΏΠΈΡΡΠ²Π°ΡΡ Π² ΡΠ΅Π΄ΠΊΠΈΡ
ΡΠ»ΡΡΠ°ΡΡ
, ΠΏΡΠ΅ΠΆΠ΄Π΅ Π²ΡΠ΅Π³ΠΎ Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ Π½Π΅ΠΊΠΎΡΠΎΡΡΡ
ΠΊΠΎΠΆΠ½ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, Π½Π°ΠΏΡ. dermatitis herpetiformis. ΠΡΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΠ°ΠΏΡΠΎΠ½ΠΎΠΌ ΡΠΎΠΆΠ΅ ΠΈΡΠΊΠ»ΡΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΠ΅Π΄ΠΊΠΈ, ΠΏΠΎΡΡΠΎΠΌΡ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΎ Π½ΠΈΡ
ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅Ρ ΠΈΠ½ΡΠ΅ΡΠ΅Ρ Π΄Π»Ρ ΡΠΎΠΊΡΠΈΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠΈ. ΠΠ΄Π΅ΡΡ ΠΌΡ ΠΎΠΏΠΈΡΡΠ²Π°Π΅ΠΌ ΡΠ»ΡΡΠ°ΠΉ ΠΎΡΡΡΠΎΠ³ΠΎ ΠΎΡΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΠ°ΠΊΡΠΎΠ½ΠΎΠΌ, Π΅Π΄ΠΈΠ½ΡΡΠ²Π΅Π½Π½ΡΠΉ Π² ΡΠ΅ΡΠΈΠΈ ΠΈΠ· 21 000 ΡΠ»ΡΡΠ°Π΅Π² ΠΎΡΡΡΡΡ
ΠΎΡΡΠ°Π²Π»Π΅Π½ΠΈΠΉ, Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΊΠΎΡΠΎΡΡΡ
ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΎΡΡ Π² ΠΊΠ»ΠΈΠ½ΠΈΠΊΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΠΊΡΠΈΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ Π£Π½ΠΈΠ²Π΅ΡΡΠΈΡΠ΅ΡΡΠΊΠΎΠΉ Π±ΠΎΠ»ΡΠ½ΠΈΡΡ βΠ‘Π². ΠΠ΅ΠΎΡΠ³ΠΈβ ΠΠΠ, ΠΠ»ΠΎΠ²Π΄ΠΈΠ², ΠΠΎΠ»Π³Π°ΡΠΈΡ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΠ΅ΡΠΈΠΎΠ΄Π° 1999 - 2013 Π³